Nilotinib buyers span pharmaceutical importers, hospital procurement networks, specialty distributors, generic manufacturers, and clinical research organizations across more than 110 countries. The most concentrated demand originates from India, the United States, Brazil, Germany, and select Southeast Asian markets, where both branded Tasigna and generic equivalents circulate through regulated supply chains. Understanding Nilotinib and Its Commercial Significance Nilotinib, marketed under the brand name Tasigna by Novartis, is a second-generation BCR-ABL tyrosine kinase inhibitor used primarily in the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). It is approved as a first-line therapy in more than 85 countries and as a second-line treatment in over 110 countries, making it one of…